An open-label extension study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension
Latest Information Update: 27 Sep 2024
At a glance
- Drugs LTP 001 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 31 Jul 2024 According to ClinicalTrials.gov , this trial was terminated due to Sponsor Decision
- 31 Jul 2024 Status changed from completed to discontinued.
- 03 Jun 2024 Status changed from recruiting to completed.